Endometrial Cancer
Conditions
Keywords
endometrial cancer, organoide, PARP inhibitor
Brief summary
This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
Interventions
OTHERtumour and blood samples
Tumour and blood samples
Sponsors
Centre Francois Baclesse
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 years or more * Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment. * Patient with localized endometrial cancer, presenting: * A high-grade endometrioid histological type and/or * P53 mutation and/or * a non-endometrioid histological type regardless of P53 status. * Patient affiliated to a social security scheme * Information and signature of informed consent prior to any specific study procedure
Exclusion criteria
* Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin). * Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of establishment of exploitable tumor organoid lines | through study completion, an average of 3 years | Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors. |
Countries
France
Contacts
Primary ContactGwenn LE GALL, Medical Doctor
Backup ContactFrançois CHERIFI, Medical Doctor
Outcome results
None listed